支气管哮喘难以根治，气道炎症及气道重塑是其主要病理机制。我们前期研究发现平喘方针对“痰气瘀互结”病理环节，治疗哮喘疗效确切，能够改善气道炎症和重塑，但机制不明。我们的预实验发现平喘方能降低RORγt并升高FOXp3，从而恢复Treg/Th17细胞平衡，降低巨噬细胞炎性蛋白-1α(MIP-1α)和IgE水平。而PI3K/Akt是RORγt和FOXp3的重要上游信号通路并能促进胶原纤维合成，可能是平喘方的重要作用环节。因此本研究将从两个层面系统阐述“平喘方→PI3K/AKT↓→FOXp3↑/RORγt↓→Treg/Thl7平衡→MIP-1α↓→改善哮喘气道炎症”以及“平喘方→PI3K/AKT↓ →α-SMA↓I型胶原↓→改善哮喘气道重塑”。这有助于平喘方作用机制的阐明，为改进平喘方从而进一步提高疗效提供理论依据。

Airway inflammation and airway remodeling is of the main pathological mechanism of bronchial asthma which is difficult to cure.Our previous research has shown that the therapeutic method of phlegm and stasis resolving and asthma relieving have regulating action on airway inflammation and airway remodeling. Our preliminary experiment showed that treatment with Pingchuan formula (PCF)downregulates RORγt, elevates Foxp3 expression which restoring Treg/Th17 balance,reduces MIP-1α and IgE level, improving airway inflammation and reducing asthma symptoms.So via the animal experiments,we will for the first time reveal that through downregulate the signaling pathways PI3K/AKT which may promote collagen also downregulates airway inflammation synthesis and further prove that maybe the important mechanism on asthma.In conclusion, our study will clarify mechanisms of PCF used to enhance therapeutic effect in asthma.